Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01875458

Enrollment

314

Registered

2013-06-11

Start date

2012-04-13

Completion date

2022-10-30

Last updated

2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Bisphosphonate Treatment, Healthy Volunteers, Osteoporosis, With or Without Treatment

Keywords

Aclasta, Actonel, alendronate, alendronate/cholecalciferol, Aredia, Atelvia, Boniva, Didronel, etidronate, Fosamax, Fosamax Plus D, ibandronate, pamidronate, Reclast, risedronate, Skelid, tiludronate, zoledronic acid, Zometa, Bisphosphonate, Atypical Femur Fracture (AFF), Osteoporosis, Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ)

Brief summary

Bisphosphonates are drugs that prevent bone loss by blocking the activity of cells that normally resorb bone. The most common examples of these drugs are Boniva and Fosamax. These drugs are available for oral or intravenous dosing and are prescribed at daily, weekly, biweekly, or monthly intervals. Among the many thousands of individuals who currently take these medications, certain individuals experience atypical femur fractures preceded by prodromal pain, changes in cortical thickening of bone, or bisphosphonate related osteonecrosis of the jaws (BRONJ). Osteonecrosis of the jaws is defined as exposed bone of the jaws for 8 weeks or more and requires surgical treatment. This study will attempt to identify genomic and rna biomarkers that may play a role in differential metabolism of bisphosphonates or indicate tendency toward the severe adverse events associated with these drugs.

Detailed description

Collected specimens were subjected to Affymetrix DMET™ Plus Solution analysis. Manuscript is in preparation.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Any adult (male or female) age 18 or over meeting any of the following criteria: * All participants must be able to provide informed consent for themselves. * History of BP treatment with or without BRONJ and/or Femur fracture (typical or atypical) * No History of BP treatment with or without BRONJ and/or Femur fracture (typical or atypical)

Exclusion criteria

* Children age 17 or younger * Adults who cannot or do not make medical decisions for themselves * Persons known to be under the jurisdiction of the Department of Corrections * Individuals who are pregnant.

Design outcomes

Primary

Measure	Time frame	Description
Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups	Baseline	DNA analysis of saliva, blood, and tissues to detect differential response to drugs. DNA will be isolated from each sample and ADME profiling will be performed. Each participant subgroup will be compared to each other using ANOVA modeling. Each participant subgroup will be compared to normative data for the distribution of gene profiles in the general population for each probe on the ADME gene array.

Secondary

Measure	Time frame	Description
Differential expression of miRNA biomarkers across participant groups within the study	Baseline	The relative abundance of miRNA across each participant subgroup will be compared using ANOVA modeling. Each participant subgroup will be compared to normative data for the distribution of miRNA expression profiles in the general population for each probe when available.

Countries

United States

Outcome results